Expecting a growth rate of 40% in FY12: Granules India

C Krishna Prasad, MD, Granules India, spoke to CNBC-TV 18 about the company's performance and what to expect in the days to come.

Below is a verbatim transcript. Also watch the accompanying video Q: You have seen about a 45% growth in your net sales and an equivalent smart improvement in your operating profits as well. Is this growth run-rate likely to continue?
A: Yes, it is likely to continue and improve as we go by quarter-on-quarter. Q: So what would FY12 and FY13 look like?
A: This year we will be having a growth rate of about 40% and next year we will be close to that. Q: In terms of key growth drivers, geographically and segment wise, where is this majority growth coming for you?
A: Geography wise it is mainly Europe, followed by the US and segment wise its PFIs and Finished Dosages together. Both have an equally impressive growth rate. Q: What about the Indian markets? Do you operate in the Indian markets at all and what would be your trajectory there?
A: We do operate in Indian market. It